SAN
FRANCISCO, Dec. 2, 2022 /PRNewswire/ -- JelloX
Biotech is celebrating a robust year of research and product
development milestones while showcasing the potential for 3D
imaging and AI to be the future of cancer pathology.
Presently, most cancer diagnosis is done through thinly sliced
physical biopsies. Though widespread, the amount of information
this method collects remains limited. JelloX envisions a future in
which AI-driven, volume-based 3D digital tumor analysis is
primarily used, leading to more comprehensive and precise diagnoses
and therefore treatments. The company recognizes that a key step
towards this future is underway: the US National Cancer Institute
(NCI) is currently conducting an open inquiry into
multidimensional atlases of tumor complexities to evaluate the
potential of these new approaches.
MetaLite®, JelloX's cost-effective software platform,
leverages AI to analyze 3D-rendered thick tissue images rapidly,
saving pathologists hours while improving diagnostic precision. The
software can easily be worked into existing pathology workflows:
biopsy samples can be first rendered into 3D images with
fluorescence labeling and clearance prior to reuse for conventional
molecular pathology analyses if needed. Unlike physical biopsies,
3D imaging can visualize multiple tumor layers in high resolution
and capture various parameters and biomarker features with a high
sampling rate to produce a meticulous diagnosis. 3D imaging is to
thin tissue biopsies what CT scans are to x-ray diagnostics in
hospitals.
"Seeing is believing," says Dr. Margaret
Chang, Chief Strategy Officer of JelloX, "and with our 3D
imaging technology, pathologists can see all the complexities of a
tumor's biomarkers — pinpointed in multidimensional renderings
instead of in a thin physical sample viewed through a
microscope."
Through its clinical research achievements, JelloX Biotech
firmly believes that 3D imaging technology and AI have the
potential to vastly improve cancer pathology. In a breakthrough
this year published in the Journal of Translational
Medicine, researchers from the company were able to use 3D
imaging to clearly evaluate tumor and biomarker heterogeneity, such
as programmed death-ligand 1 (PD-L1) often present in non-small
cell lung cancer. PD-L1 is a protein that plays a big role in
managing the body's immune response against many types of cancers.
This novel, next-generation pathology diagnostic method potentially
enhances the accuracy of assessing tumor PD-L1 expression to make
way for precise cancer immunotherapy deployment. In turn, this
matches more patients to the right drugs, broadening the potential
users and beneficiaries of this technology, and preempting a
significant social, health, and economic impact while expanding
opportunities for the pharmaceutical industry.
In another of its breakthroughs, presented in findings selected
as the best paper presentation in the 2022 European Congress of
Pathology, JelloX Biotech devised a sensitive method using
antibodies capable of detecting low concentrations of HER2 — a
protein that promotes cancer cell growth — in breast cancer
via 3D imaging and AI modeling [1]. In separate
studies, JelloX successfully leveraged the technology for research
on oral and prostate cancer diagnoses including perineural invasion
patterning and Gleason scoring.
In the coming year, JelloX Biotech will submit a Premarket
Notification 510(k) to the FDA for MetaLite®. The
company is currently looking for potential partners, particularly
to participate in the NCI request for information.
To explore research collaboration, please contact Dr.
Yen-Yin Lin, CEO of JelloX Biotech
Inc.
About JelloX Biotech Inc.
Based in Hsinchu, Taiwan,
JelloX Biotech Inc. is a startup founded by researchers from
National Tsing Hua University and focuses on advancing cancer
pathology through 3D digital imaging and AI technology. For more
information, visit https://jellox.com/en/home
[1] Lee,
et. al., Computer-aided algorithm and 3D imaging technology
are sensitive methods in the diagnosis of HER2 expression-low
breast cancers. Best paper presentation, 2022 European
Congress of Pathology (ECP), Basel, Switzerland.
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/jellox-biotech-leads-research-in-3d-cancer-pathology-as-nci-explores-potential-301692957.html
SOURCE JelloX Biotech Inc.